Edwards Lifesciences Corporation Stock CINNOBER BOAT

Equities

0REN

US28176E1082

Advanced Medical Equipment & Technology

Delayed CINNOBER BOAT 5-day change 1st Jan Change
- CHF -.--% Intraday chart for Edwards Lifesciences Corporation -.--% -.--%
Sales 2024 * 6.56B 5.89B Sales 2025 * 7.21B 6.47B Capitalization 55.66B 50B
Net income 2024 * 1.61B 1.45B Net income 2025 * 1.88B 1.69B EV / Sales 2024 * 8.23 x
Net cash position 2024 * 1.67B 1.5B Net cash position 2025 * 2.8B 2.52B EV / Sales 2025 * 7.33 x
P/E ratio 2024 *
35 x
P/E ratio 2025 *
29.7 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 91.59%
More Fundamentals * Assessed data
Dynamic Chart
Edwards Lifesciences Insider Sold Shares Worth $492,258, According to a Recent SEC Filing MT
Edwards Lifesciences Corporation Announces Executive Changes CI
Wolfe Research Adjusts Price Target on Edwards Lifesciences to $70 From $75 MT
Edwards Lifesciences Announces Results from Analysis of Data from Partner Trials Examining Outcomes of Transcatheter Aortic Valve Replacement Patients with Small Annulus CI
Transcript : Edwards Lifesciences Corporation Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 10:30 AM
Transcript : Edwards Lifesciences Corporation Presents at The 44th Annual William Blair Growth Stock Conference, Jun-04-2024 12:00 PM
Sector Update: Health Care Stocks Steady Premarket Monday MT
Becton, Dickinson to Acquire Edwards Lifesciences' Critical Care Product Division for $4.2 Billion in Cash MT
Edwards Lifesciences to sell critical care products unit to Becton Dickinson for $4.2 bln RE
Becton, Dickinson to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2 Billion MT
Becton, Dickinson and Company entered into an agreement to acquire Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW) for $4.2 billion. CI
Some of the biggest splits in Corporate America RE
Citigroup Upgrades Edwards Lifesciences to Buy From Neutral, Adjusts Price Target to $105 From $98 MT
Deutsche Bank Upgrades Edwards Lifesciences to Buy From Hold, Raises Price Target to $103 From $86 MT
Edwards Lifesciences Insider Sold Shares Worth $439,038, According to a Recent SEC Filing MT
More news
Managers TitleAgeSince
Chief Executive Officer 56 14-12-31
Director of Finance/CFO 57 13-12-31
Chief Tech/Sci/R&D Officer - 19-01-31
Members of the board TitleAgeSince
Director/Board Member 63 16-07-04
Chairman 67 14-11-12
Director/Board Member 72 16-03-15
More insiders
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows: - heart valves and surgery products (67.9%); - hemodynamic monitoring systems (15.5%); - other (16.6%): balloon catheters, artificial implants, etc. Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
92.37 USD
Average target price
96.05 USD
Spread / Average Target
+3.99%
Consensus